Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tumor DNA in fluids may predict peritoneal metastasis risk

NCT ID NCT07574957

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether tumor DNA found in blood or peritoneal fluid can predict the spread of digestive cancers (stomach, colon, pancreas) to the lining of the abdomen. Researchers will follow 300 patients with early-stage tumors to see if those with positive DNA markers are more likely to develop peritoneal metastases. The goal is to develop a less invasive way to detect this type of spread, which is currently hard to spot with imaging.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood or fluid test to predict peritoneal cancer spread, helping doctors plan treatment earlier.
What could go wrong
This is an observational study, not a treatment trial. The test may not prove accurate enough for routine use, and results are still early.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2033

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients treated for a histologically proven, localized adenocarcinoma of gastric or pancreatic or colorectal, will be enrolled in this prospective cohort study after receiving and signed a specific consent information form.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 18 years * Signed non-opposition form * For gastric cancer: histologically confirmed gastric adenocarcinoma \>T2 and/or N+; for colon cancer: histologically confirmed colonic adenocarcinoma \>T2; for pancreatic cancer: histologically confirmed pancreatic adenocarcinoma \>T2 * No metastases on the initial staging work-up * No contraindication to curative-intent surgical treatment Exclusion Criteria: * Primary tumor metastatic at diagnosis * Presence of ascites or distant metastases * Synchronous cancer or prior history of cancer within the past 5 years * Contraindication to curative surgical treatment * Any patient unable to comply with the study's medical follow-up for geographic, social, or psychological reasons * Patients under legal guardianship/protection, or unable to read, understand, and sign the information notice and consent form * Patients not affiliated with the social security system

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colonic adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colon adenocarcinoma colorectal cancer colorectal neoplasm gastric adenocarcinoma gastric cancer gastric neoplasm malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer Gastric cancer (GC) Pancreatic cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.